文献速递消化道出血消化内镜

精准局部应用氨甲环酸增强消化性溃疡出血内镜止血:一项随机对照研究(附视频)

Precise application of topical tranexamic acid to enhance endoscopic hemostasis for peptic ulcer bleeding: a randomized controlled study (with video).
PubMed 文献 · Gastrointest Endosc · 2023-06-24

本研究纳入2022年3月至2023年2月消化性溃疡出血患者,标准内镜治疗后随机分为氨甲环酸组(追加1.25 g氨甲环酸粉末喷洒)与标准组,两组均接受3天高剂量(8 mg/h)持续质子泵抑制剂输注,第3至4天行二次内镜检查。氨甲环酸组早期治疗失败率6.7%低于标准组30%(P = .042),4天和28天无治疗失败期显著更长(P = .023),未记录氨甲环酸相关不良事件。

要点

  • 标准内镜止血后追加1.25 g氨甲环酸粉末喷洒可降低早期治疗失败率。
  • 氨甲环酸组早期治疗失败率6.7%低于标准组30%(P = .042)。
  • 两组均接受3天高剂量(8 mg/h)质子泵抑制剂持续输注,第3至4天二次内镜。

核心结论

  • 在标准内镜止血基础上精准局部应用氨甲环酸降低了消化性溃疡出血患者的早期治疗失败率。

研究设计与样本

  • 随机对照研究,纳入2022年3月至2023年2月消化性溃疡出血患者,标准内镜治疗后随机分为氨甲环酸组与标准组,每组30例,共60例。

主要发现

  • 氨甲环酸组早期治疗失败率为6.7%,标准组为30%,两组比较P = .042。
  • 氨甲环酸组4天和28天无治疗失败期显著长于标准组(P = .023)。
  • 未记录氨甲环酸相关不良事件。

关键数值与推荐

  • 氨甲环酸组在标准内镜治疗后追加1.25 g氨甲环酸粉末内镜下喷洒于溃疡面。
  • 两组均接受3天高剂量(8 mg/h)持续质子泵抑制剂输注。
  • 第3至4天行二次内镜检查。
  • 早期治疗失败定义为4天内溃疡再出血或二次内镜发现近期出血主要征象。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Peptic ulcer recurrent bleeding occurs in 20% to 30% of patients after standard endoscopic hemostasis, particularly within 4 days after the procedure. The application of additional tranexamic acid (TXA) to the ulcer may enhance hemostasis. This study investigated the effectiveness of TXA powder application on bleeding ulcers during endoscopic hemostasis. METHODS: This study enrolled patients who had peptic ulcer bleeding between March 2022 and February 2023. After undergoing standard endoscopic therapy, the patients were randomly assigned to either the TXA group or the standard group. In the TXA group, an additional 1.25 g of TXA powder was sprayed endoscopically on the ulcer. Both groups then received 3 days of high-dose (8 mg/h) continuous infusion proton pump inhibitor therapy. Second-look endoscopy was conducted on days 3 to 4. The primary end point of early treatment failure was defined as ulcer recurrent bleeding within 4 days or major stigmata of recent hemorrhage on the second-look endoscopy. RESULTS: Sixty patients (30 in each group) with peptic ulcer bleeding and balanced baseline characteristics were randomly assigned to a treatment group. The early treatment failure rate was lower in the TXA group (6.7%) than in the standard group (30%) (P = .042). The freedom from treatment failure periods for 4 and 28 days was significantly longer in the TXA group than in the standard group (P = .023). No adverse events from TXA were recorded. CONCLUSIONS: The precise delivery of topical TXA alongside standard endoscopic hemostasis reduced the early treatment failure rate in patients with bleeding peptic ulcers. (Clinical trial registration number: NCT05248321.).

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Chiang HC, Chen PJ, Yang EH, et al. Precise application of topical tranexamic acid to enhance endoscopic hemostasis for peptic ulcer bleeding: a randomized controlled study (with video). Gastrointest Endosc. 2023. PMID: 37356632. doi:10.1016/j.gie.2023.06.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。